Last reviewed · How we verify

NCT06709833: 001_2024_BO2

Meningioma and Embolism Thrombosis Risk & Investigation of Coagulation

Recruiting now Last updated 6 January 2025
What this trial tests

trial in Meningeoma in 100 participants. Currently enrolling.

Timeline
16 December 2024
Primary endpoint
31 December 2025
31 August 2026

Quick facts

Lead sponsorUniversity Hospital Tuebingen
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date16 December 2024
Primary completion31 December 2025
Estimated completion31 August 2026
Sites1 location across Germany

Conditions studied

Sponsor

University Hospital Tuebingen

Who can join

18 and older, any sex, with Meningeoma or Thrombembolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Despite being generally benign tumors, meningiomas are associated with an increased risk for thrombembolic complications after surgical resection. The molecular mechanisms underlying this circumstance are still unknown. In this prospective observational trial, the investigators aim to evaluate the changes in coagulation and platelet function caused by tumor resection. Blood samples are obtained by patients undergoing meningioma resection before and immediately after resection to detect said changes. As a control cohort, blood samples are obtained from patients undergoing resection for glioma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital Tuebingen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06709833.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing